Gilead Strengthens HIV Growth Platform with Expanded Latin America Access

Gilead Sciences, Inc. (NASDAQ: GILD ) has reached an agreement with the Pan American Health Organization (PAHO) to expand access to its twice-yearly HIV-prevention drug lenacapavir across Latin America and the Caribbean. The agreement creates a regional procurement pathway through PAHO for 14 countries, including Brazil, Mexico, Argentina, Colombia and Peru, that were outside Gilead's existing voluntary generic-licensing arrangements.

Availability will still depend on individual countries' regulatory approvals and decisions to adopt the drug. Reuters notes that new HIV infections in Latin America and the Caribbean increased 13% between 2010 and 2024, highlighting a sizeable unmet prevention need. Gilead expects lenacapavir to generate about $1 billion in 2026 sales.

PAHO Deal Expands Lenacapavir's Growth Runway

The agreement could broaden lenacapavir's commercial footprint while strengthening the drug's position as Gilead Sciences, Inc. (NASDAQ:GILD)'s next major HIV growth driver. Gilead reported 12% year-over-year HIV sales growth in Q2 2026, while Yeztugo sales reached $232 million, above the $210 million analyst estimate, reinforcing management's confidence in achieving approximately $1 billion of full-year sales. Gilead subsequently raised its expected 2026 HIV-product sales growth to 9%-10%. The PAHO arrangement adds 14 markets to the access pathway and could provide a more coordinated route to government-funded procurement than country-by-country commercialization. That matters because Latin America has both rising HIV incidence and significant gaps in PrEP utilization.

The agreement also strengthens Gilead's competitive position around long-acting HIV prevention. Lenacapavir's twice-yearly dosing differentiates it from daily oral PrEP and can address adherence and supply-continuity problems associated with daily pills. Reuters reported that lenacapavir demonstrated nearly 100% efficacy in large prevention trials, while Gilead is simultaneously expanding the product into additional formulations and markets. The combination of U.S. commercial growth, international expansion, and additional licensing pathways therefore gives Gilead more opportunities to build a durable revenue stream around lenacapavir.

Local Production Could Further Constrain Commercial Returns

The principal financial limitation is that broader access does not necessarily translate into proportionate high-margin revenue. Gilead Sciences, Inc. (NASDAQ:GILD) has already granted royalty-free voluntary licenses to generic manufacturers for resource-limited countries, while its broader access strategy includes generic licensing, technology transfers, and partnerships. The PAHO pathway is specifically designed to improve regional access, meaning pricing and procurement terms could be materially lower than Gilead's commercial pricing in wealthier markets. This could constrain the revenue and margin contribution from Latin America even as patient reach expands.